BioCentury
ARTICLE | Company News

G-BA opts not to assess three older drugs

July 5, 2013 11:36 PM UTC

Germany's Federal Joint Committee (G-BA) said it will not conduct benefit assessments for three drugs launched before drug pricing law AMNOG took effect which it had previously said it would assess. G-BA noted that data exclusivity for the drugs -- osteoporosis drugs Protelos strontium ranelate from Servier (Neuilly-sur-Seine, France) and Forsteo teriparatide from Eli Lilly and Co. (NYSE:LLY) and Lilly's neurology drug Cymbalta duloxetine -- would expire around the same time as pricing negotiations based on G-BA's assessments would conclude.

G-BA is still set to assess a number of other drugs that were launched prior to AMNOG, including osteoporosis drug Prolia denosumab from Amgen Inc. (NASDAQ:AMGN) and cardiovascular drugs Xarelto rivaroxaban from Bayer AG (Xetra:BAYN) and Pradaxa dabigatran from Boehringer Ingelheim GmbH (Ingelheim, Germany) (see BioCentury Extra, April 18). ...